other material
confidence high
sentiment positive
materiality 0.50
Xeris reaffirms 2021 net sales guidance at high-end $76-80M, 55% YoY growth
Xeris Biopharma Holdings, Inc.
- Preliminary 2021 pro forma net sales expected at high-end of $76-80M guidance, ~55% growth vs 2020.
- Year-end 2021 preliminary cash, equivalents, and investments ~$102M.
- Over 20M Medicaid lives in IL, TN, PA, OH, CA now have unrestricted access to Gvoke as of Jan 1, 2022.
- Third product Recorlev approved; launch in near term; additional $30M raised early 2022.
- Full Q4 and FY 2021 results and 2022 guidance expected in March 2022.